Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma

Progression-free survival following transarterial chemoembolisation (TACE) for hepatocellular cancer (HCC) is variable. We explored targeted sequencing of circulating tumour DNA (ctDNA) as a prognostic biomarker. Plasma samples (n=23) were collected at baseline and following TACE. Targeted, ultra-deep sequencing was conducted on 18 somatic mutations related to the molecular pathogenesis of HCC.

肝细胞癌（hepatocellular cancer, HCC）患者接受经动脉化疗栓塞术（transarterial chemoembolisation, TACE）后的无进展生存期存在显著个体差异。本研究探讨了循环肿瘤DNA（circulating tumour DNA, ctDNA）靶向测序作为预后生物标志物的应用价值。研究共采集23份基线及经TACE治疗后的血浆样本，并针对与肝细胞癌分子发病机制相关的18个体细胞突变开展了靶向超深度测序。